title: [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
authors.forename: Pierre
authors.initials: P
authors.lastname: Fabries
authors.forename: Ghislain
authors.initials: G
authors.lastname: Pauleau
authors.forename: Sarah
authors.initials: S
authors.lastname: Brardjanian
authors.forename: Charles
authors.initials: C
authors.lastname: Artéaga
authors.forename: Michel
authors.initials: M
authors.lastname: Guisset
authors.forename: Thierry
authors.initials: T
authors.lastname: Coton
mesh_terms: D000307:Adrenal Gland Diseases / Q000139:chemically induced / Q000175:diagnosis; D000310:Adrenal Gland Neoplasms / Q000473:pathology / Q000556:secondary*; D000311:Adrenal Glands / Q000187:drug effects / Q000473:pathology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D006470:Hemorrhage / Q000139:chemically induced / Q000175:diagnosis; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000139:chemically induced / Q000175:diagnosis; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib